Parkside Advisors LLC Increases Stock Position in Johnson & Johnson (NYSE:JNJ)

Parkside Advisors LLC increased its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 23.4% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 3,879 shares of the company’s stock after buying an additional 735 shares during the quarter. Parkside Advisors LLC’s holdings in Johnson & Johnson were worth $685,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in JNJ. Price T Rowe Associates Inc. MD boosted its holdings in Johnson & Johnson by 18.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 24,622,795 shares of the company’s stock worth $4,370,793,000 after buying an additional 3,912,430 shares in the last quarter. FMR LLC boosted its holdings in Johnson & Johnson by 20.8% during the second quarter. FMR LLC now owns 18,725,049 shares of the company’s stock worth $3,323,883,000 after buying an additional 3,229,032 shares in the last quarter. Vanguard Group Inc. raised its position in Johnson & Johnson by 1.2% during the third quarter. Vanguard Group Inc. now owns 245,340,875 shares of the company’s stock worth $40,078,885,000 after acquiring an additional 2,815,655 shares during the period. GQG Partners LLC raised its position in Johnson & Johnson by 64.4% during the first quarter. GQG Partners LLC now owns 6,501,761 shares of the company’s stock worth $1,151,931,000 after acquiring an additional 2,547,378 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its position in Johnson & Johnson by 52.2% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 6,102,999 shares of the company’s stock worth $1,083,329,000 after acquiring an additional 2,093,392 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Piper Sandler reduced their price objective on shares of Johnson & Johnson from $55.00 to $52.00 in a research report on Monday, February 6th. Cantor Fitzgerald restated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Morgan Stanley upped their price objective on shares of Johnson & Johnson from $176.00 to $180.00 and gave the stock an “equal weight” rating in a research report on Wednesday, January 25th. Atlantic Securities upped their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Finally, Citigroup increased their target price on shares of Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research report on Monday, December 12th. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $174.73.

Insider Activity

In related news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction that occurred on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the sale, the insider now owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.35% of the company’s stock.

Johnson & Johnson Trading Down 1.1 %

Shares of JNJ stock opened at $152.38 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 0.99 and a quick ratio of 0.77. The firm has a market cap of $396.84 billion, a PE ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54. The company has a 50-day moving average of $161.97 and a two-hundred day moving average of $167.88. Johnson & Johnson has a 1-year low of $150.71 and a 1-year high of $186.69.

Johnson & Johnson (NYSE:JNJ – Get Rating) last announced its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $23.71 billion during the quarter, compared to analyst estimates of $23.90 billion. During the same quarter last year, the firm posted $2.13 earnings per share. Johnson & Johnson’s revenue was down 4.4% compared to the same quarter last year. On average, analysts predict that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were paid a $1.13 dividend. This represents a $4.52 annualized dividend and a dividend yield of 2.97%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s payout ratio is 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.